Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
Open accessThe DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index; none of the 86 sources its claims cite is checked for support yet.
Abstract
At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence.
Overview
CoChat Summary
## TL;DR
This review argues that poor medication adherence in type 2 diabetes is common, often affecting at least half of patients, and is tied to worse glycemic control, higher costs, and higher mortality. It highlights two broad modifiable drivers: treatment burden and patients’ treatment-related beliefs.
## Key findings
- Reported poor medication adherence in T2D ranged from 38% to 93% across studies, largely because definitions and methods varied; using MPR ≥80%, adherence was 47.3% for dipeptidyl peptidase-4 inhibitors, 41.2% for sulfonylureas, and 36.7% for thiazolidinediones in a 238,000-patient MarketScan analysis.
- Poor adherence was associated with worse outcomes: among >11,000 veterans, MPR <80% was significantly associated with poor glycemic control (HbA1c >8%, P<0.001); in 1,198 survey respondents, each 1-point drop in self-reported adherence was linked to a 0.21% increase in HbA1c and increases of 4.6%, 20.4%, and 20.9% in physician, ER, and hospital visits.
- Mortality was higher with poor adherence: in 15,984 UK patients, poor adherence and missed visits were each associated with a 1.6-fold increase in all-cause mortality (P<0.001); another study reported an odds ratio of 1.8 (P<0.001).
- Economic impact was substantial: improved adherence was projected to reduce hospitalization/ER risk by 13%, worsening adherence to raise it by 15%, and one analysis estimated annual savings of $4.7 billion with improved adherence and $3.6 billion with reduced poor adherence.
## Methods
- Narrative review of the literature on medication adherence in T2D, focusing on the scope of the problem, consequences, key contributors, interventions, and future developments.
- The paper synthesizes findings from retrospective/observational claim-database studies, surveys, and meta-analyses; it cites examples including analyses of 238,000 MarketScan patients, >11,000 veterans, 1,198 survey respondents, and other large database studies.
- Main analysis is qualitative synthesis of reported adherence rates, outcomes, and modifiable contributors, with attention to common adherence metrics such as medication possession ratio (MPR) ≥80% and persistence definitions.
## Limitations
- The paper states that much of the evidence comes from retrospective or observational claim-database studies using widely varying definitions, making findings difficult to interpret.
- It states that intervention evidence is limited because adherence measures vary widely, hard outcomes are often lacking, interventions are not clearly explained, and follow-up is often inadequate.
- Evident from the text: this is a review, not a new primary study, so its conclusions depend on the quality and comparability of the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 1 Not valid · 57 Not checked · 17 Own results and interpretations
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In one study that tracked new prescriptions written electronically over a 12-month period for >75,000 patients, 31.4% of new prescriptions for diabetes drugs were never filled.25”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Scope of the problem
What the sources say
- Not matchedcites [25]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainn = 75,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia)”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
49 more claims
Create a free account to see all 75 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple factors contribute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication ef fi cacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2DM who discontinue or do not properly adhere to their therapy, there is an increased risk of microvascular and macrovascular complications [7], which can in turn increase healthcare costs further [5, 6].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from this survey highlight patient perspectives on reasons for treatment discontinuation among people with T2DM in the USA and UK and provide focal points for communication for these individuals when they are initiating new therapies [5].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the NICE guidance (NG28) and gastrointestinal tolerability are likely important drivers, early GLP‐1RA discontinuation is plausibly multifactorial and may also reflect perceived treatment effectiveness, complex dosing schedules, injection‐related barriers, limited access to diabetes education, economic constraints, and medication shortages. 19 , 32 , 33 , 34”
From Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Up to 50% of people with T2DM discontinue treatment by 1 year [5].”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945 · cited 2×
“65 A key element is the need for greater consistency when measuring medication adherence, which require better instruments and tools for assessment.”
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70021-0 · Cited by 1,195
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837 · cited 1×
“Even worse, it has been well documented that this cost burden has been inexorably growing worldwide.(10) A key contributor to the remarkably high rates of morbidity and mortality is chronic poor metabolic control, especially poor glycemic control.”
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726 · cited 1×
“41 In their comprehensive review of 76 studies, Claxton et al 42 found that the prescribed number of doses per day was inversely associated with medication adherence; indeed, the mean adherence across studies decreased progressively from 79% with a once-daily dose to 51% with a four times daily…”
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationPrimary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions
Fischer, M. A., Stedman, M. R., Lii, J., Vogeli, C., Shrank, W. H., Brookhart, M. A., & Weissman, J. S. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1253-9 · Cited by 572 · cited 1×
“25 This problem, often referred to as primary nonadherence, may be particularly relevant among patients who are refusing to initiate insulin or other injectable hypoglycemic therapy, typically due to injection phobia, inconvenience, poor patient–physician communication, and/or negative patient…”
Cited by
Items 701–761 of 761
Factors associated with diabetes distress in older patients with type 2 diabetes mellitus
Liu, Y.-L., Tsai, W.-I., Huang, Y.-M., Ming-Yuan, H., & Lee, C.-H. (2026) · Educational Gerontology · doi:10.1080/03601277.2026.2615380
Fukui, M., Tsuboi, S., Yamamoto, Y., & Terauchi, Y. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01839-7
“A continual movement towards the individ-ualization of treatment regimens in Japan has likely contributed to the increased number of therapies and treatment regimens available, each of which has potential implications for individual adherence, persistence, and, therefore, glycemic control [38].”
Pasambo, Y., Murti, F. A. K., Ferry, E., et al. (2026) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s563957
ALSHAMMAR, S. M. A. A. H. (2026) · Medical Reports · doi:10.1016/j.hmedic.2026.100417
Pan, J., Xue, X., Li, H., & Wu, L. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343091
“The results were consistent with a study that showed low education level as a crucial factor responsible for poor adherence to T2DM therapy [47].”
Meng, Z., Gao, X., Zhou, X., et al. (2026) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.143007
“Do You Understand What I Am Saying?”: Exploring Language Practices in Describing Life With Diabetes
Gonzalez, J., Crossman, R., & Spiers, J. A. (2026) · Global Qualitative Nursing Research · doi:10.1177/23333936261426775
Medication Adherence and Its Associated Factors among Type-2 Diabetes Mellitus Patients
Mangrati, J., & Hemank, K. C. (2026) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v16i3.7628
Lalam, B., Ezatiru, L., Okusa, J. M., Akello, S., Opito, R., Lubogo, P., Eleku, S., Nabidda, S., Kabwigu, S., & Okello, S. (2026) · BMC Family Practice · doi:10.1186/s12875-026-03267-9 · Cited by 1
“Other factors include; inadequate health education, and weak patient–provider relationships [7, 17, 18].”
Yang, M., Zhou, D., He, L., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-107509
Grundlagen des Diabetesmanagements
Kulzer, B., Aberle, J., Haak, T., Kaltheuner, M., Kröger, J., Landgraf, R., & Kellerer, M. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01462-x
Soma, M. S. N., Vyshnavi, J., Bhavin, V. S., Hoque, J., & Chinnaeswaraiah, M. (2026) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-026-04331-0
“Poor compliance could be an indication of poor health literacy and psycho-social stress levels [27, 28].”
Treatment of Youth‐Onset Type 2 Diabetes: Focus on SGLT‐2 Inhibitor Use
Arslanian, S. A., Barrett, T. G., & Shehadeh, N. (2026) · Pediatric Diabetes · doi:10.1155/pedi/4555805
“…being a lack of research into adherence to recently approved injectable therapies in youth-onset T2D, there are well-known adherence issues associated with injectable insulin in young patients, thus highlighting the need for new and effective oral therapies in this population [25, 52, 53].”
Développement de nanovecteurs innovants destinés au traitement de la leishmaniose viscérale.
Matha, K. (2020) · theses.fr (ABES) · doi:10.70675/16804747z40f4z45a2zb4eczcd7e166ef1a8 · Cited by 1
Hu, R., Jagannath, S., Mougenot, C., & Porat, T. (2026) · doi:10.2196/preprints.97367
Gautham, K., Holla, S. K., & Dasara, B. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01648-5
Ha, R., Kim, C., Hwang, S.-S., & Jung‐Choi, K. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e172
Calzada, F., Ruedaflores, Y. L., Mendieta‐Wejebe, J. E., Ramírez-Santos, J., Valdes, M., Velázquez, C., & Barbosa, E. (2026) · Molecules · doi:10.3390/molecules31091393
Hayashi, S., Konaka, K., & HAMADA, R. (2026) · Cureus · doi:10.7759/cureus.107766
Mallisetty, Y., Chaudhary, S., Ellis, A. W., Shah, R. S., & Surbhi, S. (2026) · Diabetology · doi:10.3390/diabetology7050086
Rawashdh, N. A., Patel, B. V., Wang, S. M., Zur, R. M., Anaya, P., Kahn, E. B., Pinsker, J. E., Sasson-Katchalski, R., Trahan, A. C., Messer, L. H., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70759
“Conversely, improved adherence has been shown to reduce the risk of hospitalization or emergency room visits by 13% [40].”
Assaad-Khalil, S. H., Abdelaaty, T., Rizk, M. N., Megallaa, M. H. Z., Elsayed, M., Wafa, A. M., Ismail, A., Sharafeldeen, B., & Amin, N. G. (2026) · Diabetology · doi:10.3390/diabetology7050090
“Challenges to achieve glycemic control are exacerbated in Egypt by high clinic work-loads, limited access to structured diabetes education, inconsistency in follow-up, and cost sensitivity, all of which negatively affect adherence and timely treatment intensification [11,12].”
InfluentialFatal suicides by insulin injection: a retrospective medico-legal case series from Türkiye
Doğan, M., Erdoğmuş, A., İlhan, C. K., & Üzün, İ. (2026) · Canadian Society of Forensic Science Journal · doi:10.1080/00085030.2026.2660431
“Poor glycemic control, sedentary lifestyle, and antipsychotic non-adherence may further amplify both metabolic instability and suicidal behavior in these patients [1,39,40].”
Srusti, H. G., Darshini, K., Poorvika, K. V., & Rout, B. (2026) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v16i5.7739
Kiyosue, A., Inoue, M., Takita, Y., Nasu, R., & Watada, H. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01860-w
“However, most people with T2D treated with insulin do not achieve good glycemic con-trol [9] due to challenges such as the complexity of treatment regimens, fear of hypoglycemia, delays in insulin initiation and intensification, and suboptimal insulin dosing [10–13].”
What Is the Current State of Stem Cell Therapy in Diabetes?
Bakinowska, E., Biniek, W. J., Kiełbowski, K., Dyrka, K., Szewczyk, K., Ostałowska, H., Leciej, Z., & Pawlik, A. (2026) · Cells · doi:10.3390/cells15100907
“Aside from adverse events, the treatment of T2DM patients is frequently ineffective because of suboptimal adherence [10].”
Giese, I. E., Laursen, S. H., Barington, P. F., Vestergaard, P., & Hangaard, S. (2026) · JMIR Formative Research · doi:10.2196/89964
“This self-management includes performing complex care activities, making lifestyle adjustments, and sustaining adherence to prescribed medication [3-5].”
Permatasari, L., Andayani, T. M., & Rahmawati, F. (2026) · Journal of Pharmaceutical And Sciences · doi:10.36490/journal-jps.com.v9i2.1526 · Cited by 1
Muyisa, R. M., Watumwa, E. J., Sivulyamwenge, A. K., & Mwalitsa, J. P. P. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70183 · Cited by 4
Kezza, L. N. Y., Kooko, R., Musoke, D., Rutebemberwa, E., Nakisita, O., Dandy, M. W. W., & Somse, P. (2026) · medRxiv · doi:10.64898/2026.06.02.26354687
Лагода, Д. (2026) · Здобутки клінічної і експериментальної медицини · doi:10.11603/1811-2471.2026.v.i2.16405
Lim, B., Githinji, P., Liao, Y., Szeszulski, J., Uribe, A. L. M., Seguin‐Fowler, R. A., Anderson, J., & Rethorst, C. D. (2026) · JMIR Formative Research · doi:10.2196/85897
“Interventions emphasizing diet and physical activity are widely recommended to control glucose; however, these interventions often overlook the multifaceted dynamic physiological and behavioral influences on glycemic control [7,8].”
Yeşilyurt, A. G. K., & Erkayman, B. (2026) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2026.06.005
Zegeye, M. Y., SofiyaYimerMengesha, & Hussen, S. (2026) · BMC Public Health · doi:10.1186/s12889-026-28268-2
“The tool was developed based on an extensive review of relevant literature [11, 21, 24–27].”
Araújo, L. D. C., Lourenço, V. D. S., Fagundes, V. D. C., de Oliveira, A. F., Prete, A. C. L., Ribeiro, C. H. M. A., Sarges, É. D. S., Margalho, L. P., Paixão, P. A. R., Dornas, S. G. B., et al. (2026) · Pharmacoepidemiology · doi:10.3390/pharma5030020 · Cited by 1
Polonsky, W. H., Low, E., Dias-Barbosa, C., Clark, A., Bailey, K., Ilag, L., GONCALVES, L. F., Threlkeld, R. J., Child, C. J., Davidson, M. B., et al. (2026) · Patient · doi:10.1007/s40271-026-00829-y
Self-citationAllama, L., Saeed, S. N., Alhaffar, M. B. A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9997655/v1
Kumar, I. S., Panesar, S., Jaiswal, R. K., Roy, N., & Dhamnetiya, D. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02417-5
“Medication adherence, regular follow-up visits, and timely modification of treatment regimens are essential components of effective diabetes management [12].”
Hao, X., Liu, L., Li, P., Lei, C., Tong, Y., Dong, J., Liu, X., Cheng, X., Zhao, J., Min, X., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113437
Cw, C., Wu, T.-H., Lee, P.-C., et al. (2026) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001405
Telehealth and Pharmacist-led Interventions in Diabetes Management
Ahmad, N. A., & Hussain, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26472-6.00195-9
Rungnoei, N., Kruttakart, S., Phianthanyakam, N., Klinhom, P., Nokpaet, U., Sirikunwiwat, J., & Jaitham, B. (2026) · Journal of Health Research · doi:10.56808/2586-940x.1209
Ali, I., Mahamdeh, S., Dawod, H., & Alshaer, S. (2026) · Research Square · doi:10.21203/rs.3.rs-10325928/v1
Dahal, P., Lakshmi, K., & Alam, K. (2026) · Journal of Applied Pharmaceutical Science · doi:10.1177/22313354261464248
“15 Similarly, the increase in the HRQoL EQ-5D index score was modest (EQ-5D-5L: +0.04) but statistically significant, suggesting a small improvement in HRQoL among intervention groups within the short study duration.”
InfluentialImpact of community pharmacist interventions on medication adherence in chronic disease patients
Mandava, J. (2026) · Journal of Community Pharmacy Practice · doi:10.55529/jcpp.61.20.30
Jinnouchi, H., Inoue, M., Takita, Y., Nasu, R., & Threlkeld, R. J. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01902-3
“A key contributing factor is poor medication adherence [2,3], which poses a considerable challenge to the effective management of T2D.”
Shanmugam, P., Adams, R. N., Athinarayanan, S. J., Wolfberg, A., & Ballreich, J. M. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01909-w
Wang, T., & Shiyanbola, O. O. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01639-0
“Sustained use of GLP-1–based therapies reflects both pharmacologic effects and how treatment is introduced and supported in clinical care [29, 35].”
InfluentialAnsari, M. (2026) · Medicine · doi:10.1097/md.0000000000049485
“[10,11] Inadequate glycemic control, a higher risk of complications (such as heart attacks and strokes, nephropathy, retinopathy, and kidney failure), more hospital admissions, and higher healthcare costs can all result from poor medication adherence.”
Lin, N. A., Reddy, S., & Lee, W. (2026) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-26-00366
Bahari-Moghaddam, P. N., Mobasseri, M., Ranjbari, S., Asadi, E., Shojaie-Dizaji, L., Khakpaki, A., & Farshbaf‐Khalili, A. (2026) · European Journal of Nutrition · doi:10.1007/s00394-026-04091-8
“This treat - ment gap is attributable to several factors, including medication-related adverse effects, high treatment costs, limited access to newer therapeutic agents, and poor long-term adherence, particularly in resource-limited environments [9 , 10 ].”
Janež, A., Bojić, M., Božek, T., Kamenov, Z. A., Milenković, T., Radulian, G., & Várkonyi, T. T. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1905393
Hegaz, M. G., Aboud, M. Y. A., Kamel, A. I. I., Naveed, M. A., Elsayad, O. G., & Sorathia, A. Z. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02538-x
“Orforglipron’s oral administration offers a distinct advantage over injectable GLP-1 RAs, potentially improving accessibility and adherence [49].”
Wang, D., Nida, G., Hardesty, V., & Livingston, K. A. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261488712
dos Santos, J. M., Dechant, J., Zhu, J., Seth, T., Rohay, J. M., Heck, T. G., & Dunbar‐Jacob, J. M. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02794-2
IcoSema in Weight Management and Glycaemic Control: A Systematic Review and Meta-Analysis
Nouh, M. I., Karrar, H. R., Albuti, H., Alhendi, R. S. A., Alharbi, S. A., Alfakih, S. M., Thabit, F. Y., Abdulrahman, M. A. E., Aman, A. M., Murshid, G. M., et al. (2026) · Cureus · doi:10.7759/cureus.116875
Moklesur, M., Islam, M. N., Simon, N. P., Islam, T., Naser, A. Z. M., Hafez, S., & Hasan, R. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104815
Determinants and patterns of medication adherence among individuals with type 2 diabetes mellitus
Sultana, J., Khan, M. M., Ali, M. N., Samia, N. A., Sristy, U. S., Billah, M., & Khan, M. A. H. (2026) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20263587
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Metadata
- Authors
- Polonsky, W., & Henry, R.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Polonsky, William
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2016-07
- Volume
- Volume 10
- Pages
- 1299-1307
- ISSN
- 1177-889X (ISSN-L)
- PMC
- PMC4966497
- OpenAlex
- W2493860075
- Cited by
- 784
- References
- 77
- Citations by year
- 2026: 93 · 2025: 97 · 2024: 89 · 2023: 82 · 2022: 108 · 2021: 106 · 2020: 106 · 2019: 54 · 2018: 34 · 2017: 13 · 2016: 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Preference and Adherence (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- medication adherence, type 2 diabetes, glycemic control, barriers to adherence, medication beliefs, medication burden, out-of-pocket costs, hypoglycemia, treatment complexity, clinical inertia, socioeconomic factors, diabetes complications, drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.